• 약학회지
• /
• 제27권2호
• /
• pp.133-138
• /
• 1983

The interaction between nalidixic acid and probenecid was studied pharmacokinetically in rabbits. The blood level and the area under the concentration curve(AUC) of nalidixic acid administered orally in dose of 100mg/kg was elevated by the coadministration of probenecid. Probenecid inhibited both the urinary excretion and the biliary excretion of nalidixic acid. Therefore, biological half-life of nalidixic acid was prolonged by the coadministrarion of probenecid. It was considered that the coadmini-stration of probenecid is more desirable than the single administration of nalidixic acid for the therapeutic effect.

• 약학회지
• /
• 제29권4호
• /
• pp.216-219
• /
• 1985

The phormacokinetics of acetaminophen were investigated in rabbits with folate-induced renal failure. The blood level, the area under the blood concentraction curve(AUC) and the biological half-life were increased significantly, and the urinary excretion was decreased significantly as compared with those of normal rabbits. Serum creatinine concentration and AUC, creatinine clearance and renal clearance have linear relationship respectively. Dosage regimen of acetaminophen was considered to be adjusted in renal failure.

• 한국환경농학회:학술대회논문집
• /
• 한국환경농학회 2011년도 30주년 정기총회 및 국제심포지엄
• /
• pp.282-282
• /
• 2011

• 생물정신의학
• /
• 제21권2호
• /
• pp.74-80
• /
• 2014

Objectives More than half of the elders suffer from chronic sleep disturbances. Moreover, sleep disturbances are more prevalent in patients with depressive disorder than in community dwelling elderly. In this study, we aim to estimate the risk factors of poor sleep quality and its effect on quality of life in patients with late life depression. Methods This study included 159 depressive patients aged 65 years or older who completed Pittsburgh Sleep Quality Index (PSQI). A global PSQI score of 5 or greater indicates a poor sleeper. Structural diagnostic interviews were performed using the Korean version of Mini International Neuropsychiatric Interview (MINI). Depression was evaluated by the Korean form of Geriatric Depression Scale (KGDS). Global cognition was assessed by Mini-Mental State Examination in the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease assessment packet. Quality of life was evaluated by the Korean version of Short-Form 36-Item Health Survey (SF-36). Results The frequencies of poor sleepers were 90.5% in major depressive disorder, 71.8% in minor depressive disorder, 47.1% in subsyndromal depressive disorder, and 73.0% in all types of depressive disorders. Multivariate logistic regression analysis indicated that female [odds ratio (OR) = 2.83, 95% confidence interval (CI) = 1.20-6.67] and higher KGDS score (OR = 1.13, 95% CI = 1.05-1.21) were risk factors of poor sleep quality in patients with late life depression. In the analysis of ANCOVA adjusted for age, gender, education and KGDS score, the mean scores of vitality mental health and mental component summary of SF-36 were lower in poor sleepers than in good sleepers. Conclusions Poor sleepers among patients with late life depression are very common and are associated with female and higher KGDS scores. Poor sleep quality causes a significant negative effect on mental health quality. So researchers and clinicians should be more vigilant in the evaluation and treatment of sleep disturbances in patients with late life depression.

• 한국환경농학회지
• /
• 제36권1호
• /
• pp.50-56
• /
• 2017

본 연구는 수박 중 pyridalyl 및 fluopicolide의 경시적 잔류양상을 살펴보고 생산단계 잔류허용기준 설정을 위한 생물학적 반감기를 산출하고자 수행되었다. 두 시험약제를 안전사용기준에 따라 두 포장지역에서 각각 살포한 후 포장 1에서는 10일간 포장 2에서는 20일간 일자별 수박 시료를 채취하여 각각의 잔류분을 HPLC/UVD로 분석하였다. 두 시험농약의 분석정량한계는 각각 0.05 mg/kg, 0.02 mg/kg이었으며, 회수율은 81.2~90.5% 수준이었고 시료 중 시험농약은 43~47일간 안정하였다. 수박 중 초기 잔류량은 pyridalyl이 0.12~0.16 mg/kg, fluopicolide은 0.23~0.24 mg/kg이었으며, 모든 포장내에서 농약잔류허용기준보다 낮은 수준이었다. 수박 중 pyridalyl의 생물학적 반감기는 포장 1에서 26.9일, 포장 2에서 17.9일 이었으며, fluopicolide의 생물학적 반감기는 포장 1에서 16.6일, 포장 2에서 94.2일이었다. 수박의 pyridalyl 및 fluopicolide의 수확 10일 전 생산단계 잔류허용기준은 각각 0.21 mg/kg, 1.03 mg/kg이었으며 재배기간 중 두 시험약제 모두 매우 낮은 잔류소실 경향을 보였다.

• 대한수의학회지
• /
• 제40권1호
• /
• pp.35-41
• /
• 2000

We established a new method to analyze abamectin using HPTLC (high performance thin layer chromatography) in order to obtain its pharmacokinetic profiles in pigs. Recovery of abamectin in pig serum after fluorescence derivatization was $80.01{\pm}3.82%$ at 0.1ppm and $83.67{\pm}3.63%$ at 10ppm, respectively. Detection reproducibility in terms of coefficient variation (c.v.) was 3.09% and 2.74% (intra-day), and 3.71% and 51.7%(inter-day), for 0.1 and 10ppm, respectively. Pharmacokinetics of abamectin was studied in five Yorkshire-Landrace mixed bred male pigs ($35.0{\pm}2.7kg$) administered intramuscularly 0.3mg/kg b.w. Pharmacokinetic profiles of abamectin in pigs were described by the 1-compartment open model with first-order absorption and first-order elimination. AUC (area under the curve) was $262.65{\pm}16.44ng{\cdot}day/ml$ and the biological elimination half-life ($t_{1/2},\;k_e$) was $5.28{\pm}0.84$ days, indicating somewhat high bioavailability and long half-life by the intramuscular route. We suggest intramucular injection of abamectin could be also used in place of the recommended route of its subcutaneous administration so far.

• 대한디지털의료영상학회논문지
• /
• 제13권4호
• /
• pp.153-156
• /
• 2011

This study, which is proceeded in the department of nuclear medicine, aims at preventing unnecessary radiation exposure to the patients and the people near the patients by understanding and presenting the realities about the isolating period for the high dose radioiodine patients after total thyroidectomy in the 7 general hospitals in metropolitan area. Theoretically, the physical half-life of the high dose radioiodine is 8 days. Radioiodine lower than 100 mCi usually is eliminated all in 2 days 1 night considering the biological half-life and the amount of excreting radioiodine The hospitalization standard of the patients treated with high-dose radioiodine therapy has been established according to the fact above. Investigation of the data and questionnaire from the hospital have proven that some hospitals didn't even measure the acceptable dose because of the faith in the vague data. Besides, the some of those inevitably let the readmitting patients exceeding the acceptable dose be in the general ward, not in the isolation ward, because the number of the isolation rooms is relatively smaller than the patients. Thus, we want to contribute that patients understand the realities and the hospitals consider the relevant problem actively so that the problem will be settled by this journal.

• 방사선산업학회지
• /
• 제9권4호
• /
• pp.193-198
• /
• 2015

Most of targeted therapies block the action of certain enzymes, proteins, or other molecules involved in the growth and spread of cancer cells to produce its cytotoxic effect. Either small molecule drugs or monoclonal antibodies are mostly used in targeted therapies. Unfortunately, targeted therapy has a certain degree of unwanted side effect like other cytotoxicity inducing chemotherapies. To overcome and to reduce unwanted side effects during a cancer therapy, recently radiopeptide therapies has got the worlds' attraction for the tumor targeting modalities due to its beneficial effect on less side effect compared to cytotoxic chemotherapies. Among radiopeptide therapies, $^{177}Lu$-DOTATATE is a major modality as an effective one invented so far in treating neuroendocrine tumor (NET) and it has been in clinical trials at least one decade. Although it does have rather effective therapeutic effect on NET, it has less effective in rather large solid tumor. There are many ways to improve or increase therapeutic effect of radiopeptide are a finding the potent small molecules to target the tumor site selectively, or a labeling with radioisotope of emitting high energy, or an improving its biological half-life by introducing different moieties to increase lipophilicity. Present study was focus to increase a biological half-life of radio somatostatin which will target the somatostatin receptor by altering the bifunctional chelator (BFCA) by introducing lipophilic moiety to the somatostatin, which would make the labeled peptide stay longer in the tumor site and thus it can intensify the therapeutic effect on tumor cell itself and around tissues.

• 약학회지
• /
• 제15권2호
• /
• pp.41-52
• /
• 1971

Cu(II) chelates of several sulfanilamide derivatives (Sulfa-Cu) were prepared and their effects on solubility, absorptivity in intestinal lumen, biding tendency with serum protein and erythrocytes, concentration in rabbit blood, and acetylation rate were studied in comparison with their free ligand forms. For solubility concerned, the partition coefficients of Sulfa-Cu are decreased as following order: Sulfadimethoxine Copper chelate (SDM-Cu), Sulfamethoxypyridazine Copper chelate (SD-Cu), Sulfamerazine Copper chelate (SM-Cu), Sulfaisoxazole Copper chelate (SIX-Cu). The partition coefficients of SDM-Cu and ST-Cu were much greater than those of ligands. this phenomenone acounts for the rapid absorption of SDM-Cu and ST-Cu in the rat small intestine (in situ). The Sulfa-Cu were absorbed at the intestinal lumen of a rat in the rate of first order and there was no difference between long acting sulfa drugs and their Cu0chelates in biological half lives. In binding experiments, sulfa-Cu binded with serum protein in lower ratio than their ligands except SIX-Cu. On other hand, acetylation rates of sulfa-Cu were higher than those of free sulfa drugs and the acetylation rate were higher than those of free sulfa drugs and powder. In a experiment on Sulfa-Cu concentration in rabbit blood, the half lives of SD-Cu, SIX-cu, ST-Cu, and SM-Cu were longer than those of their ligands. Above all, the half life of SD-Cu appeared to be approximately 3.5 times logner than that of corresponding ligand, SD. When absorption of sulfa drugs or sulfa-Cu at the small intestinal lumen of a rat and the concentration in rabbit blood after absorption were compared, it was found that there was not always conrrelated.

• 농약과학회지
• /
• 제21권1호
• /
• pp.17-25
• /
• 2017

대추 중 boscalid와 pyraclostrobin의 잔류량을 조사하여 약제별 잔류소실과 생물학적 반감기를 산출하였다. 노지재배 중인 대추에 안전사용기준 농도로 희석한 boscalid와 pyraclostrobin을 다른 두 지역의 포장에서 각각 살포 후 0 (2시간), 1, 3, 5, 7, 10, 14일에 시료를 채취하여 HPLC/DAD로 분석하였다. 두 시험농약의 방법정량한계는 $0.02mg\;kg^{-1}$이었으며 시험분석법의 회수율 결과, boscalid는 101.8~109.3%, pyraclostrobin은 104.2~115.4%이었다. 저장안정성시험 결과, boscalid는 101.9~106.5%, pyraclostrobin은 104.6~110.6%이었으며 회수율시험 및 저장안정성 시험 결과 CV값이 5% 미만이었다. 대추 중 boscalid의 초기 잔류량은 포장 1에서 $0.40mg\;kg^{-1}$이고 포장 2에서 $0.48mg\;kg^{-1}$이었으며, pyraclostrobin의 초기 잔류량은 포장 1에서 $0.76mg\;kg^{-1}$이고 포장 2에서 $0.57mg\;kg^{-1}$이었다. 대추 중 boscalid의 생물학적 반감기는 포장 1에서 11.0일, 포장 2에서 13.2일 이었으며, pyraclostrobin의 생물학적 반감기는 포장 1에서 6.1일, 포장 2에서 12.7일이었다.